Understand the source comparison
Comparison: GHRP-6 vs. Other Growth Hormone Secretagogues
| Secretagogue | Primary Receptor | Somatostatin Resistance | GH Pulse Amplitude (vs. Baseline) | Secondary Pathways | Half-Life (Subcutaneous) | Practical Research Use ||—|—|—|—|—|—|| GHRP-6 Acetate | GHS-R1a + CD36 | High. Retains 60–70% potency under SRIF |
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Secretagogue | Primary Receptor | Somatostatin Resistance | GH Pulse Amplitude (vs. Baseline) | Secondary Pathways | Half-Life (Subcutaneous) | Practical Research Use ||—|—|—|—|—|—|| GHRP-6 Acetate | GHS-R1a + CD36 | High. Retains 60–70% potency under SRIF | 3–5× baseline | CD36-mediated lipid modulation, appetite stimulation | 2–4 hours | Pituitary responsiveness testing, metabolic flexibility studies, appetite regulation models || GHRP-2 | GHS-R1a | Moderate. 40–50% potency under SRIF | 4–6× baseline | Minimal off-target binding | 2–3 hours | Pure GH secretion protocols where appetite effects are undesirable || Ipamorelin | GHS-R1a (highly selective) | Low. Minimal activity under tonic SRIF | 2–3× baseline | None significant | 2 hours | Selective GH stimulation without ghrelin-like side effects (no hunger, no cortisol/prolactin elevation) || MK 677 | GHS-R1a | Very high. Non-peptide agonist | 2–4× baseline (sustained 24h) | Appetite stimulation, IGF-1 upregulation | 24 hours (oral